Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Wednesday. They currently have a $6.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 233.33% from the stock’s previous close.

Several other equities research analysts also recently commented on APTO. ValuEngine downgraded Aptose Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Roth Capital reiterated a “buy” rating and set a $5.00 target price on shares of Aptose Biosciences in a report on Monday, October 23rd. Canaccord Genuity set a $7.00 target price on Aptose Biosciences and gave the company a “buy” rating in a report on Wednesday, November 15th. Finally, Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Friday, November 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $5.00.

Shares of Aptose Biosciences (NASDAQ APTO) opened at $1.80 on Wednesday. Aptose Biosciences has a twelve month low of $0.78 and a twelve month high of $2.30.

COPYRIGHT VIOLATION WARNING: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/aptose-biosciences-apto-price-target-raised-to-6-00-at-hc-wainwright/1760855.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.